sogroya market analysis, sogroya market growth, sogroya market forecast, sogroya market insights, sogroya market size, sogroya market trends
What are the recent trends in market size and growth for the sogroya market?
The sogroya market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to the rise in the medically underserved, the rise in demand for related treatments, the rise in concern about passenger safety, the increase in diagnosis, and the increasing access to innovative pharmaceuticals.
The sogroya market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to growing government initiatives, increasing trends in urban lifestyles, growing the rate of growth hormone diseases, growing healthcare awareness, and growing sectors in the pharmaceutical industry. Major trends in the forecast period include technological innovations, advancements in biotechnology and recombinant DNA technology, advancements in drug delivery systems, AI for personalized treatment, and a shift toward preventive medicine.
Get Your Free Sample of The Global Sogroya Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20358&type=smp
How have varous drivers impacted the growth of the sogroya market?
The increasing demand for hormone replacement therapy (HRT) is anticipated to boost the growth of the sogroya market in the coming years. HRT is a medical treatment designed to replace hormones like estrogen and progesterone to address symptoms associated with menopause or hormonal imbalances. Hormone replacement therapy (HRT) is increasing due to the rising prevalence of hormonal imbalances, greater awareness of its benefits, and advancements in medical treatments that make it more accessible and effective for managing conditions such as menopause and growth hormone deficiencies. Sogroya supports hormone replacement therapy by providing a once-weekly treatment option for patients with growth hormone deficiency, helping to restore normal growth hormone levels, improve physical function, and enhance overall quality of life with a convenient and effective dosing regimen. For instance, in October 2023, according to the National Health Service, a UK-based government department, the UK reported 11 million HRT prescriptions in England during 2022-23, representing a 47% increase from 2021-22. Furthermore, around 2.3 million patients received HRT prescriptions, reflecting a 29% rise compared to the previous year. Therefore, the growing demand for hormone replacement therapy is driving the expansion of the sogroya market.
What are the primary segments of the sogroya market?
The sogroya market covered in this report is segmented –
1) By Indication: Adult Growth Hormone Deficiency; Pediatric Growth Hormone Deficiency
2) By Formulation: Subcutaneous Injectable; Pre-Filled Syringes
3) By Distribution Channel: Retail Pharmacies; Online Pharmacies
4) By End User: Hospital; Clinicals; Ambulatory Care
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/sogroya-global-market-report
Which firms are leading the sogroya market?
Major companies operating in the sogroya market are Novo Nordisk A/S
How will industry trends affect the trajectory of the sogroya market?
The key trend in the sogroya market is the increasing focus on gaining regulatory approvals to expand its indications and improve accessibility. Regulatory approvals refer to the official authorization by government agencies to ensure a drug’s safety, efficacy, and quality before it can be marketed or prescribed. For instance, in April 2023, Novo Nordisk A/S, a Denmark-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Sogroya, used for the treatment of children aged 2.5 years and older with growth hormone deficiency, making it the first once-weekly growth hormone therapy available for both pediatric and adult patients. This innovative treatment allows for subcutaneous injection just once a week, offering a more convenient alternative to daily injections. The approval is based on the phase 3 REAL4 study, which demonstrated comparable height velocity outcomes between Sogroya and traditional daily somatropin. Common side effects include nasopharyngitis, headache, and injection site reactions.
Which geographic trends are shaping the sogroya market, and which region has the highest market share?
North America was the largest region in the sogroya market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sogroya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Sogroya Market Report 2025 Offer?
The sogroya market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Sogroya (somapegsomatropin) is a long-acting growth hormone treatment used for the treatment of adults with growth hormone deficiency (GHD). It is designed to provide the benefits of growth hormone replacement therapy with the convenience of once-weekly injections, improving patient adherence to treatment.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20358
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
